Second Primary Malignancies Represent Small Proportion of Adverse Events After CAR T-Cell Therapy
Most reports of SPMs included axicabtagene ciloleucel and tisagenlecleucel; most frequent SPMs were leukemias
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.